Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

Heidenreich S, Ziagkos D, De Wreede LC, Van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yanez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachee P, Selleslag D, De Witte T, Robin M, Kroeger N (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 23

Pages Range: 44-52

Journal Issue: 1

DOI: 10.1016/j.bbmt.2016.09.027

Abstract

In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients ≥ 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients’ seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P = .01) and 46% (P = .002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS.

Involved external institutions

Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Leiden University Netherlands (NL) Paracelsus-Elena-Klinik Kassel Germany (DE) Universitätsklinikum Freiburg Germany (DE) Technische Universität Dresden Germany (DE) Universität Leipzig Germany (DE) Eberhard Karls Universität Tübingen Germany (DE) HELIOS Kliniken Germany (DE) Universitätsklinikum Essen Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ Israel (IL) Asklepios Kliniken Verwaltungsgesellschaft mbH Germany (DE) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven Belgium (BE) Marqués de Valdecilla University Hospital / Hospital Universitario de Marqués de Valdecilla (HUMV) Spain (ES) University of Liège (ULg) / Université de Liège Belgium (BE) Universität zu Köln Germany (DE) Westfälische Wilhelms-Universität (WWU) Münster Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Hospital Network Antwerp / Ziekenhuis Netwerk Antwerpen (ZNA) Belgium (BE) AZ Sint-Jan Netherlands (NL) Radboud University Nijmegen Netherlands (NL) Hôpital Saint-Louis AP-HP France (FR)

How to cite

APA:

Heidenreich, S., Ziagkos, D., De Wreede, L.C., Van Biezen, A., Finke, J., Platzbecker, U.,... Kroeger, N. (2017). Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biology of Blood and Marrow Transplantation, 23(1), 44-52. https://doi.org/10.1016/j.bbmt.2016.09.027

MLA:

Heidenreich, Silke, et al. "Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT." Biology of Blood and Marrow Transplantation 23.1 (2017): 44-52.

BibTeX: Download